Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5960507 | 0.85 | HRH3 (0.51) | CASP3SENP8SENP7SENP6KDM4E | |
| SCHEMBL20875018 | 0.80 | KIF11 (0.51) | KDM4EALDH1A1HPGDHSD17B10PARP1 | |
| SCHEMBL30071313 | 0.80 | ALOX15 (0.48) | CHEK2ITK | |
| SCHEMBL19463968 | 0.80 | ALOX15 (0.48) | CHEK2ITK | |
| SCHEMBL31721323 | 0.79 | CASP3 (0.60) | CASP3SENP8SENP7SENP6KDM4E | |
| SCHEMBL30445643 | 0.79 | HSD17B10 (0.61) | CASP3SENP8SENP7SENP6KDM4E | |
| SCHEMBL69851 | 0.79 | HSD17B10 (0.61) | CASP3SENP8SENP7SENP6KDM4E | |
| SCHEMBL5868213 | 0.78 | CASP3 (0.58) | CASP3SENP8SENP7SENP6KDM4E | |
| SCHEMBL233323 | 0.78 | CASP3 (0.58) | CASP3SENP8SENP7SENP6KDM4E | |
| SCHEMBL30339870 | 0.78 | CASP3 (0.58) | CASP3SENP8SENP7SENP6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-24 | — | — | US | disclosed |
| CN-115650985-B | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| CN-115650985-A | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-10 | — | — | US | disclosed |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-10 | — | — | US | disclosed |
| EP-3960180-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2022-03-02 | — | — | EP | disclosed |
| EP-3960180-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2022-03-02 | — | — | EP | disclosed |
| EP-3442980-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-06-09 | — | — | EP | disclosed |
| EP-3442980-B1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-06-09 | — | — | EP | disclosed |
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECH LTD (GB) | 2021-05-27 | — | — | US | disclosed |
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECH LTD (GB) | 2021-05-27 | — | — | US | disclosed |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | disclosed |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | disclosed |
| WO-2017178844-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155628-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | CASP3 1399/4885SENP8 3757/4885SENP7 3878/4885 |
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | CASP3 1399/4885SENP8 3757/4885SENP7 3878/4885 |
| US-20190106425-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, REL, BCR | CASP3 1399/4885SENP8 3757/4885SENP7 3878/4885 |
| US-11548896-B2 | Heterocyclic compounds as RET kinase inhibitors | RET, REL, BCR | CASP3 1399/4885SENP8 3757/4885SENP7 3878/4885 |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | CASP3 1399/4885SENP8 3757/4885SENP7 3878/4885 |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | RET, REL, BCR | CASP3 1399/4885SENP8 3757/4885SENP7 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.